• Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach 

      Aga, Anna-Birgitte; Hammer, Hilde Berner; Olsen, Inge Christoffer; Uhlig, Till; Kvien, Tore Kristian; Heijde, Desirée van der; Fremstad, Hallvard; Madland, Tor Magne; Lexberg, Åse; Haukeland, Hilde; Rødevand, Erik; Høili, Christian; Stray, Hilde; Noraas, Anne Lindtner; Hansen, Inger Johanne Widding; Bakland, Gunnstein; Lillegraven, Siri; Lie, Elisabeth; Haavardsholm, Espen A. (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-12-16)
      Objective: To develop and validate a responsive and feasible ultrasound inflammation score for rheumatoid arthritis (RA). Methods: We used data from cohorts of early RA (development) and established RA starting/switching biologic therapy (validation). 4 tendons and 36 joints were examined by a grey scale (GSUS) and power Doppler semiquantitative ultrasound (PDUS) scoring system (full score). ...
    • Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials 

      Jørgensen, Kristin Kaasen; Goll, Guro Løvik; Sexton, Joe; Bolstad, Nils; Olsen, Inge C.; Asak, Øivind Wessel; Berset, Ingrid Prytz; Blomgren, Ingrid; Dvergsnes, Katrine; Florholmen, Jon; Frigstad, Svein Oskar; Henriksen, Magne; Hagfors, Jon; Huppertz-Hauss, Gert; Haavardsholm, Espen Andre; Klaasen, Rolf Anton; Moum, Bjørn; Noraberg, Geir; Prestegård, Ulf; Rydning, Jan Henrik; Sagatun, Liv; Seeberg, Kathrine; Torp, Roald; Vold, Cecilia; Warren, David J.; Ystrøm, Carl Magnus; Lundin, Knut Erik Aslaksen; Kvien, Tore Kristian; Jahnsen, Jørgen (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-09-23)
      <i>Background</i> - The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn’s disease (CD) in the main trial displayed a close to significant difference favouring originator infliximab, and more scientific data have therefore been requested.<p><p> <i> ...
    • Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial 

      Haavardsholm, Espen A.; Aga, Anna-Birgitte; Olsen, Inge Christoffer; Lillegraven, Siri; Hammer, Hilde Berner; Uhlig, Till; Fremstad, Hallvard; Madland, Tor Magne; Lexberg, Åse; Haukeland, Hilde; Rødevand, Erik; Høili, Christian; Stray, Hilde; Noraas, Anne Lindtner; Hansen, Inger Johanne Widding; Bakland, Gunnstein; Nordberg, Lena Kristine Bugge; Heijde, Desirée van der; Kvien, Tore Kristian (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-08-16)
      Objective: To determine whether a treatment strategy based on structured ultrasound assessment would lead to improved outcomes in rheumatoid arthritis, compared with a conventional strategy. <p>Design: Multicentre, open label, two arm, parallel group, randomised controlled strategy trial. <p>Setting: Ten rheumatology departments and one specialist centre in Norway, from September 2010 to ...